Thus, although all of the disease-associated MEK1 mutants are constitutively active, the somatic MEK1 mutants found in sporadic primary cancers are highly catalytically active and efficiently induce oncogenic transformation, whereas the germline MEK1 mutants detected in RASopathies are relatively moderately active and are therefore essentially non-oncogenic. This evidence concerns the gene MAP2K1 and cancer.